NASDAQ:PTIE - Pain Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.09 -0.01 (-0.91 %)
(As of 02/18/2019 10:59 AM ET)
Previous Close$1.10
Today's Range$1.0650 - $1.12
52-Week Range$0.76 - $10.87
Volume179,056 shs
Average Volume332,444 shs
Market Capitalization$18.77 million
P/E RatioN/A
Dividend YieldN/A
Beta2.1
Pain Therapeutics, Inc. develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease. The company was founded in 1998 and is based in Austin, Texas.

Receive PTIE News and Ratings via Email

Sign-up to receive the latest news and ratings for PTIE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:PTIE
CUSIP69562K10
Phone512-501-2444

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.47 per share

Profitability

Net Income$-11,910,000.00

Miscellaneous

Employees9
Market Cap$18.77 million
OptionableNot Optionable

Pain Therapeutics (NASDAQ:PTIE) Frequently Asked Questions

What is Pain Therapeutics' stock symbol?

Pain Therapeutics trades on the NASDAQ under the ticker symbol "PTIE."

When did Pain Therapeutics' stock split? How did Pain Therapeutics' stock split work?

Shares of Pain Therapeutics reverse split on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Pain Therapeutics stock prior to the reverse split would have 14 shares after the split.

How were Pain Therapeutics' earnings last quarter?

Pain Therapeutics, Inc. (NASDAQ:PTIE) posted its quarterly earnings data on Monday, October, 29th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.61) by $0.50. View Pain Therapeutics' Earnings History.

When is Pain Therapeutics' next earnings date?

Pain Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February 18th 2019. View Earnings Estimates for Pain Therapeutics.

Has Pain Therapeutics been receiving favorable news coverage?

Headlines about PTIE stock have trended somewhat positive recently, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pain Therapeutics earned a coverage optimism score of 1.6 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future.

Who are some of Pain Therapeutics' key competitors?

Who are Pain Therapeutics' key executives?

Pain Therapeutics' management team includes the folowing people:
  • Mr. Remi Barbier, Founder, Chairman, CEO & Pres (Age 59)
  • Dr. Nadav Friedmann, COO, Chief Medical Officer & Director (Age 76)
  • Mr. Eric J. Schoen, Chief Financial Officer (Age 51)
  • Dr. Michael Marsman Pharm.D., Sr. VP of Regulatory Affairs

Who are Pain Therapeutics' major shareholders?

Pain Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.31%), Geode Capital Management LLC (0.38%) and Virtu Financial LLC (0.20%). Company insiders that own Pain Therapeutics stock include Armistice Capital Master Fund, Armistice Capital, Llc and Sanford Robertson. View Institutional Ownership Trends for Pain Therapeutics.

Which institutional investors are selling Pain Therapeutics stock?

PTIE stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have sold Pain Therapeutics company stock in the last year include Armistice Capital Master Fund and Armistice Capital, Llc. View Insider Buying and Selling for Pain Therapeutics.

Which institutional investors are buying Pain Therapeutics stock?

PTIE stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC and BlackRock Inc.. View Insider Buying and Selling for Pain Therapeutics.

How do I buy shares of Pain Therapeutics?

Shares of PTIE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pain Therapeutics' stock price today?

One share of PTIE stock can currently be purchased for approximately $1.09.

How big of a company is Pain Therapeutics?

Pain Therapeutics has a market capitalization of $18.77 million. Pain Therapeutics employs 9 workers across the globe.

What is Pain Therapeutics' official website?

The official website for Pain Therapeutics is http://www.paintrials.com.

How can I contact Pain Therapeutics?

Pain Therapeutics' mailing address is 7801 NORTH CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The biopharmaceutical company can be reached via phone at 512-501-2444 or via email at [email protected]


MarketBeat Community Rating for Pain Therapeutics (NASDAQ PTIE)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  154 (Vote Outperform)
Underperform Votes:  198 (Vote Underperform)
Total Votes:  352
MarketBeat's community ratings are surveys of what our community members think about Pain Therapeutics and other stocks. Vote "Outperform" if you believe PTIE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTIE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2019 by MarketBeat.com Staff

Featured Article: Return on Investment (ROI)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel